Implications of AI in HealthCare
The applications of artificial intelligence (AI) in healthcare are countless. For many pharmaceutical companies, machine learning is the most important aspect of AI, with the potential to allow machines to ultimately surpass the intelligence levels of humans. The success of AI in drug discovery is largely due to hardcore Research & Development in learning section of brain sciences, a field of machine learning that is built using artificial neural networks that model the way neurons in the human brain talk to each other. This technology can turn bots into dynamically agile than the human beings. The type of artificial intelligence (AI) which scares some of the greatest minds, like Elon Musk and Stephen Hawking, is called "general artificial intelligence" - the one which can "think" pretty much like humans do, and which can quickly evolve into a dangerous "superintelligence". There is a notion that it might be invented in the nearest decades, but today we are definitely not there yet. The AI which is making headlines these days is a "narrow artificial intelligence", a limited type of machine "intelligence" able to solve only a specific task or a group of tasks. It can't go anywhere beyond specifics of the problem for which it is designed, so apparently, it will not hurt anyone in the nearest time. But already now it can provide meaningful practical results on those narrow tasks, like natural language processing, image recognition, controlling self-driving cars, and helping develop new drugs more efficiently. With the ability to find hidden and unintuitive patterns in vast amounts of data in ways that no human can do, AI represents a considerable promise to transform many industries, including pharma and biotech. The interest in AI-driven solutions for early stage drug discovery is growing steadily among biopharma leaders with a projected market volume reaching $10B by 2024 (for AI-based medical imaging, diagnostics, personal AI assistants, drug discovery, and genomics). The last couple of years were marked by a wave of new R&D collaborations between key biopharma players and AI-driven companies, primarily startups. Let's see who is doing what in the biopharmaceutical AI landscape & to get the deep dive, reserve your Spot Now at 6th Drug Discovery Innovation Programme going to be held on 29-30 November 2018 at Frankfurt, Germany.